A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.
- Conditions
- MedDRA version: 24.0Level: LLTClassification code 10080960Term: Hereditary angioedema type IISystem Organ Class: 100000004850Hereditary Angioedema Type I or IIMedDRA version: 21.0Level: LLTClassification code 10080956Term: Hereditary angioedema type ISystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Registration Number
- EUCTR2021-000136-59-BG
- Lead Sponsor
- Kalvista Pharmaceuticals Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 48
1) Male or female subjects 18 years of age and older.
2) Confirmed diagnosis of HAE type I or II at any time in the medical history.
3) Subject has access to and ability to use conventional treatment for HAE attacks.
4) Subject is willing to cease any current medications being taken for HAE prophylaxis and Investigator determines that doing so would not place the subject at any undue safety risk.
5) Subject’s last dose of attenuated androgens was at least 28 days prior to randomization.
6) During the Run-in Period subject meets one of the following criteria:
a) Two Investigator-confirmed attacks in the first 4-week period.
b) Three Investigator-confirmed attacks in =8 weeks.
7) Subjects who are fertile and heterosexually active must adhere to contraception requirements throughout the trial as follows:
a) Female subjects must agree to use at least one highly effective contraception method from the Screening Visit until the end of the trial. Highly effective methods of contraception include:
i) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral/injectable/implantable (hormonal contraception that contains estrogen including ethinylestradiol is excluded per Exclusion 4).
ii) Intrauterine device (IUD).
iii) Intrauterine hormone–releasing system (IUS).
iv) Bilateral tubal occlusion.
v) Vasectomized partner (provided that the partner is the sole sexual partner of the female subject of childbearing potential and that the vasectomized partner has received medical assessment of surgical success).
b) Male subjects with a female partner of childbearing potential must agree to use condoms for the entire Treatment Period AND for 90 days following the final dose of investigational medicinal product (IMP). Female partners are encouraged to use contraception as outlined in Inclusion 7a) from the Screening Visit until the end of the trial. Hormonal contraception that contains estrogen including ethinylestradiol is acceptable for the female partner.
8) Subjects who are not fertile or not sexually active, as defined below, do not require contraception.
a) Subjects who refrain from heterosexual intercourse during the trial if the reliability of the heterosexual abstinence has been evaluated in relation to the duration of the clinical trial and is the preferred and usual lifestyle of the subject.
b) Male subjects who are surgically sterile (e.g. vasectomized with medical assessment of surgical success).
c) Female subjects who are surgically sterile (e.g. status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 46
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 2
1) Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
2) A clinically significant history of poor response to C1-INH therapy or plasma kallikrein inhibitor therapy, for the management of HAE, in the opinion of the Investigator.
3) Use of angiotensin-converting enzyme (ACE) inhibitors after the Screening Visit or within 7 days prior to randomization.
4) Any estrogen containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) after the Screening Visit or within 7 days prior to randomization.
5) Use of narrow therapeutic index drugs metabolized by CYP3A4 or CYP2C9 or transported by OAT1, OCT2, and OATP1B1 starting at screening, as determined by the Investigator.
6) Use of strong CYP3A4 inhibitors and inducers during participation in the trial, starting at the Screening Visit. Note: These medications include but are not limited to the following: Inhibitors: boceprevir, clarithromycin, cobicistat, dasabuvir, denoprevir, elvitegravir, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, and voriconazole. Inducers: apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John’s Wort.
7) Inadequate organ function including but not limited to:
a) Alanine aminotransferase (ALT) > 2x ULN.
b) Aspartate aminotransferase (AST) > 2x ULN.
c) Bilirubin direct > 1.25x ULN.
d) International normalized ratio (INR) > 1.2.
e) Clinically significant hepatic impairment defined as a Child-Pugh B or C.
f) Estimated glomerular filtration rate (eGFR) <60 mL/min.
8) Any clinically significant comorbidity or systemic dysfunction that, in the opinion of the Investigator, would jeopardize the safety of the subject by participating in the trial.
9) History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.
10) Known hypersensitivity to KVD824 or placebo or to any of the excipients.
11) Any prior use of any gene therapy treatment for HAE.
12) Participation in any interventional investigational clinical trial within 4 weeks of the last dosing of investigational drug prior to screening.
13) Any pregnant or breastfeeding subject.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To demonstrate the clinical efficacy of prophylactic treatment with KVD824 compared with placebo in preventing hereditary angioedema (HAE) attacks.;Secondary Objective: To further characterize the clinical efficacy of KVD824.<br>To investigate the safety and tolerability of KVD824.;Primary end point(s): The primary endpoint of this trial is the rate of Investigator-confirmed HAE attacks during the Treatment Period.;Timepoint(s) of evaluation of this end point: 12 Weeks
- Secondary Outcome Measures
Name Time Method Secondary end point(s): • Proportion of subjects without Investigator-confirmed HAE attacks during the Treatment Period.<br>• Rate of Investigator-confirmed HAE attacks that require conventional treatment during the Treatment Period.<br>• Angioedema Quality of Life Questionnaire (AE-QoL) total score and domain scores during the Treatment Period.<br>• Angioedema Control Test (AECT) score and domain scores during the Treatment Period.<br>• Proportion of subjects with an AECT score =12 at the end of the Treatment Period.;Timepoint(s) of evaluation of this end point: 12 Weeks